Sam Fazeli - Profile and Journalist Details
Find journalists that align with your industry, location and vision. Unlock Sam Fazeli's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.
Get connected with journalists today
Sam Fazeli
Verified
Director of Research, Global Industries, Bloomberg Línea
London
Beats
What’s On Content , Breaking News
Content
By Sam Fazeli Verified, Lisa Jarvis Verified|Bloomberg OpinionVerifiedThe US government will soon stop paying for vaccines, monoclonal antibodies and drugs like Paxlovid. That's bad news for already-weak demand. Covid-19 funding in the US has nearly run out and unless Congress renews it, consumers could soon find themselves on the hook for vaccines and treatments that were previously free.
By Therese Raphael Verified, Sam Fazeli Verified|The Guam Daily PostVerifiedNo sweat, we’ve got this. That’s what we thought when the monkeypox outbreak emerged in May. After all, as an orthopoxvirus, it’s similar to smallpox and so we already have a vaccine — two, in fact. There is also a treatment, it’s generally not deadly, and, as a DNA virus (as opposed to an RNA one like SARS-CoV-2), it’s unlikely to mutate much. But monkeypox has proved more stubborn than many thought, and governments have been slow to roll out vaccines.
By Sam Fazeli Verified, Lisa Jarvis Verified|Bloomberg OpinionVerifiedThe US government will soon stop paying for vaccines, monoclonal antibodies and drugs like Paxlovid. That's bad news for already-weak demand. Covid-19 funding in the US has nearly run out and unless Congress renews it, consumers could soon find themselves on the hook for vaccines and treatments that were previously free.
Company Info
Bloomberg Línea